PATENT CLAIM ANALYSIS

Application Number: 16070146
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-02
Patent Classification: ["514", "277000"]

Abstract:
Provided are a pharmaceutical composition exhibiting therapeutic efficacy against EML4-ALK-positive non-small cell lung cancer that has acquired resistance to an ALK inhibitor and a method for treating the non-small cell lung cancer. Further, provided is information for drug selection for determining whether to administer a statin-based drug to a patient group with EML4-ALK-positive non-small cell lung cancer.

Claim (Index 13):
The method of  claim 11 , wherein the resistance to the ALK inhibitor is resistance to one or more ALK inhibitors selected from a group consisting of crizotinib, ceritinib, alectinib, brigatinib, and entrectinib.

Metadata:
- Claim Count in Document: 10.0
- Percentile: 95.0
- Lexical Diversity: 1.42857
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14131183', '15039442', '16062399', '14956620', '14424595']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.789191824467609
- 35 USC 102 Novelty (BERT): 0.5228397348835033
- Combined Prediction Score: 0.7625566155091985
- Mean Citation Score: 289.36938
- Max Citation Score: 314.6617700000001
- Similarity Product: 237.0828034489496

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test